Limited Submission Opportunities
(Applications through LSO office)
- Pre-app deadline: Sept 26, 2022
Blavatnik National Awards for Young Scientists
This program honors America’s most innovative young faculty-rank scientists and engineers in three disciplinary categories: Life Sciences, Physical Sciences and Engineering, and Chemistry. - Pre-app deadline: Sept 28, 2022
NIH NIGMS Collaborative Program Grant for Multidisciplinary Teams
Purpose: to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. - Internal deadline: Oct 3, 2022
Damon Runyon Clinical Investigator Award
Purpose: to support outstanding young physician-scientists doing work aimed at improving the practice of cancer medicine, by providing them with the resources and training structure essential to becoming successful clinical investigators. - Internal deadline: Oct 3, 2022
Moore Inventor Fellows
Aims to identify outstanding inventors and innovators who harness science and technology to enhance the conduct of scientific research, strengthen environmental conservation, or improve the experience and outcomes of patient care. - Internal deadline: Oct 24, 2022
W.M. Keck Foundation Medical Research Program
Purpose: to advance the frontiers of medicine, science, and engineering to benefit humanity by supporting pioneering high-risk/high-impact research projects.
Intramural Funding Opportunities
- Deadline: Sept 26, 2022
UCSF Resource Allocation Program (RAP) Fall 2022 Cycle
The UCSF Resource Allocation Program (RAP) offers a single online application process for a variety of intramural grants. Grants of interest include:- Team Science Grant ($75,000)
- Mentored Scientist Award in Pancreas Cancer ($50,000)
- Pilot Award for Pancreas Cancer ($50,000)
- Global Cancer Pilot Award ($40,000)
- Informing Tobacco Product Regulation ($50,000)
- Environmental Health Research Pilot Award ($50,000)
- Pilots for Early Career Investigators and Established Investigators ($40,000 - 50,000)
- Deadline: Oct 31, 2022
Clinical Research Staff Research Project Support RFA
The UCSF Helen Diller Family Comprehensive Cancer Center is requesting applications from Clinical Research staff to support research conference travel or publication fees. - Deadline: Nov 1, 2022
UC President's Postdoctoral Fellowship Program
This program was established in 1984 to encourage outstanding women and minority Ph.D. recipients to pursue academic careers at the University of California. The current program offers postdoctoral research fellowships and faculty mentoring to outstanding scholars in all fields whose research, teaching, and service will contribute to the diversity and equal opportunity at the University of California. - Deadline: Nov 4, 2022
UCSF Program for Breakthrough Biomedical Research
This program to stimulate and support highly innovative basic science research at UCSF. We seek novel ideas for projects that go beyond those that receive funding from NIH and other traditional funding mechanisms. - Deadline: Nov 28, 2022
Prostate Cancer Program 2022 Research Pilot Funding Awards
The UCSF Prostate Cancer Program seeks to fund pilot projects in any area of prostate cancer research. Funds are available to support multiple proposals.
Foundations/Other Sources
- Deadline: Sept 22, 2022
Conquer Cancer Foundation Young Investigator Award
The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment. - Deadline: Sept 28, 2022
HHMI Freeman Hrabowski Scholars Program
HHMI is seeking creative and innovative early career faculty for our new Freeman Hrabowski Scholars Program. Scholars will receive generous and flexible support, including full salary and benefits, a research budget of approximately $2 million over the first five years, and eligibility to participate in HHMI capital equipment purchasing programs. Contact [email protected] if you plan to apply. - Deadline: Oct 20, 2022
Conquer Cancer Foundation Career Development Award
The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program.
NIH Announcements
If you are a Cancer Center member who is interested in applying and receiving grant writing support, please contact Erin Bank.
-
Supplement for your NCI grant: Apply for Administrative Supplements to Support Cancer Disparity Collaborative Research (PAR-22-114)
If you are an investigator who holds an active and eligible NCI-funded award (parent grant), not focused on cancer disparities, and are interested in expanding your research in the cancer disparities arena through collaboration, you are eligible!
The HDFCCC is aligning resources around a new administrative supplement opportunity and needs to hear from interested applicants and potential collaborators in order to best support applications.
If you are interested, and meet the criteria for an applicant or collaborator, please indicate your interest by filling out this short form.
Please contact Kaya Balke ([email protected]) with any questions. YOU DO NOT HAVE TO IDENTIFY A COLLABORATOR OR COMMIT TO PARTICIPATE at this point. We are just getting a sense of interest. More information, including a directory of potential collaborators in the areas of cancer disparities to follow.
Applicant: an investigator who holds an active and eligible NCI-funded award (parent grant), not focused on cancer disparities, and is interested in expanding their research in the cancer disparities arena through collaboration. Additionally, the applicant should not have served previously as a Principal Investigator (PI) on a cancer disparities research grant. The applicant serves as the PI of the Supplement and will identify a collaborator with whom to implement the proposed cancer disparities research project.
Collaborator: the investigator with whom the applicant will collaborate to implement the proposed cancer disparities research project. The collaborator should have a track record in conducting research (as demonstrated by publication record and/or funding support) in the areas of cancer disparities and/or minority health research. They will bring non-overlapping yet complementary expertise to the collaboration.
Cancer Disparities Research: addresses the disproportionate cancer burden among racial/ethnic minority and/or underserved populations and seeks to understand and/or reduce differences in cancer outcomes. This research spans across the cancer continuum (prevention, early detection, diagnosis, treatment, and survivorship) and includes comparative biological, behavioral, environmental, social, clinical, or translational investigations among one or more racial/ethnic minority or underserved group. In contrast to minority health research (see below), disparities research is a comparative analysis between two different racial/ethnic minority and/or underserved groups, or one racial/ethnic minority and/or underserved group in different settings and/or environments.
Minority Health Research: is the scientific investigation of distinctive health characteristics and attributes of racial/ethnic minority groups who are underrepresented in biomedical research.
- NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
- Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
To view NCI funding opportunities, search here